title: Pyelolithotomy in a patient with Glanzmann thrombasthenia and antiglycoprotein IIb/IIIa antibodies: the shortest possible duration of treatment with recombinant activated factor VII and platelet transfusions.
abstract: Transfusion of platelet concentrates remains the first-line therapy for Glanzmann thrombasthenia in case of bleeding or preparation for surgery. However, development of antibodies to platelet glycoprotein (Gp) IIb/IIIa complex or human leukocyte antigens (HLA) is frequent and the main cause of platelet refractoriness. Recombinant activated factor VII (rFVIIa) is a potent alternative for patients with Glanzmann thrombasthenia with anti-platelet antibodies. We describe a case of Glanzmann thrombasthenia with alloantibodies to platelet Gp IIb/IIIa complex who underwent a successful pyelolithotomy operation under the coverage of recombinant activated factor VIIa and platelet transfusions.
authors.affiliation: Division of Hematology/Oncology, Istanbul University Istanbul Faculty of Medicine, Istanbul, Turkey.
authors.forename: Omer
authors.initials: O
authors.lastname: Devecioğlu
authors.forename: Ayşegül
authors.initials: A
authors.lastname: Unüvar
authors.forename: Sema
authors.initials: S
authors.lastname: Anak
authors.forename: Ilmay
authors.initials: I
authors.lastname: Bilge
authors.forename: Haluk
authors.initials: H
authors.lastname: Ander
authors.forename: Orhan
authors.initials: O
authors.lastname: Ziylan
mesh_terms: D002675:Child, Preschool; D015942:Factor VIIa / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D017713:Platelet Transfusion; D013915:Thrombasthenia / Q000601:surgery / Q000628:therapy*
chemical_list: D015942:Factor VIIa